The latest

News

Latest news131

Closeup of iris and pupil in eyeball

Ray Therapeutics Licenses Delivery Technology for Optogenetics Therapy

"Visual optogenetics is a disruptive technology which affords the opportunity to restore life-transforming levels of vision to blind and visually impaired patients with conditions such as retinitis pigmentosa,” said Paul Bresge, chief executive officer of Ray Therapeutics. “We have developed a next generation bioengineered optogenetic payload which we believe is optimized for human vision." Read post
BrightEdge's Farnaz Bakshi (center) presents Golden Ticket to Brad Niles, CEO of ARIZ (third from left) along with the BrightEdge and Bakar Labs teams

ARIZ and Catena Awarded Golden Tickets to Bakar Labs, Sponsored by ACS BrightEdge Fund

With the Golden Tickets, ARIZ and Catena each win one year of free office and lab space at Bakar Labs and access to BrightEdge’s robust network of resources to develop their cancer therapies. They will be able to access Berkeley campus resources, connect with Bakar Labs' business affiliates, and network with more than 30 fellow tenant companies. The combination of support from Bakar Labs and BrightEdge will, most importantly, allow ARIZ and Catena to bring their technology to patients sooner. Read post
Ben R. Taft

Via Nova’s Ben Taft on Challenges and Opportunities in Structure-Activity-Relationship Studies

Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space. Read post
Sampling Human co-founders Daniel Georgiev, Martin Cienciala, and Hynek Kasl (L-R) at Ocean Beach shortly after their arrival in San Francisco from the Czech Republic.

Tenant Spotlight on Sampling Human: Using Biology to Analyze Biology

Anyone who’s had a blood draw as a patient – in short, everyone – knows that what the doctor gets to work with is a basic count of red and white blood cells. But there’s so much information that we’re missing, which could help inform and develop much more precise treatment. Daniel Georgiev and Sampling Human want to solve this problem. Their solution: using biology to analyze biology. Read post
A large pile of empty yellow barrels with radioactivity warning labels.

First Drug Trial in US for Pill To Guard Against Nuclear Accidents

HOPO 14-1 is an investigative drug that is hoped can protect and treat victims of nuclear fallout, by binding (or chelating) contaminated heavy metals and removing them from the body. It is thought to be effective against Uranium and other materials used in nuclear weapons, such as dirty bombs or ballistic missiles. Read post
Katy Digovich

“Can I Cure My Diabetes With Stem Cells?” Katy Digovich Delivers TED Talk

CEO Katy Digovich recently gave a passionate TED Talk about her motivation for launching and leading Minutia. A former Princeton basketball player, Katy lives with diabetes. Working with the Clinton Global initiative in Africa, she learned that people with diabetes in the Third World face an early death sentence due to the cost of insulin monitoring and delivery. Minutia is developing cell therapy in the form of cells engineered with nanosensors to measure insulin levels and deliver dosage. Read post
The Regel Therapeutics leadership team

Tenant Spotlight on Regel Therapeutics: A New Approach to Gene Therapy

“I always used to enjoy science and technological innovation. For a scientist, curiosity leads to discovery, but it is a need that leads to invention. In the back of my mind, I always knew that to make a clinical product into a reality, I have to take the technology out of the lab and develop it in an industry setting. Patients and their caregivers motivated me to take this leap into entrepreneurship," says Navneet Matharu. Read post
Ray Therapeutics homepage with close-up of human face and eye

Ray Therapeutics: Anatomy Of A Biopharma VC Deal

Until 2010, leading a biotech wasn’t on Paul Bresge's radar. He’d built a long and successful career as a leader in unrelated industries -- industrial tools and a courier service, for example. Then, his 15-year-old daughter was diagnosed with retinitis pigmentosa, a rare genetic disease that causes degradation of retinal cells over time. She was going blind. Ophthalmologists told him there was nothing that could be done to save his daughter’s vision. Read post